News

13 Aug: LSO RESPONDS TO THE PMPRB’S JUNE 2020 DRAFT GUIDELINES CONSULTATION

Life Sciences Ontario remains deeply concerned about the federal government’s patented medicine price controls and their potential to undermine the life sciences sector’s efforts to support the health and well-being of Canadians and the economy, particularly during the unprecedented COVID-19 pandemic. There is a growing body of evidence showing that…

02 Jun: LSO supports delay of federal drug pricing rules implementation

Life Sciences Ontario applauds the federal government’s recent decision to delay the implementation of the Patented Medicines Regulations to January 1, 2021 as part of the response to the COVID-19 crisis. This measure will help the Canadian life sciences sector remain unwaveringly focused on developing vaccines, treatments, and other tools to fight…

03 Feb: New federal drug pricing rules are already delaying medicine launches and costing jobs in Canada, survey reveals

To help measure the impacts of the federal government’s new price controls for patented medicines in Canada, Life Sciences Ontario commissioned Research Etc., an established Toronto research firm, to conduct an anonymous survey of pharmaceutical and other life sciences leaders. The survey, which drew on data from 46 respondents including leaders…

10 Jan: MEMBER ANNOUNCEMENT: adMare BioInnovations and Accel-Rx Unite to Advance the Canadian Life Sciences Sector

Vancouver, Canada – January 9, 2020: With a shared vision to be a catalyst for Canadian life sciences leading the world, adMare BioInnovations, Canada’s Global Life Sciences Venture (adMare), and Accel-Rx, Canada’s Health Sciences Accelerator (Accel-Rx), announced today they are bringing their respective capabilities and resources together under adMare to…

09 Dec: New data demonstrates that federal price controls on medicines are already driving decisions to delay or not launch new therapies in Canada, reduce clinical trial investments and stall compassionate access and patient support programs

Life Sciences Ontario commissioned Research Etc., an established Toronto research firm, to conduct a survey of pharmaceutical and other life sciences leaders on the Canadian price regulations policy environment. Preliminary results of the survey are now available, drawing on 23 responses from unique organizations representing Canadian and global pharma leaders….